Tag Archives: BIO Events

Session Recap: “Trust Your Gut” – Therapeutic Opportunities from the Microbiome

Kaylee_dna_115x76

Tuesday at the BIO CEO & Investor Conference kicked off with a Therapeutic Workshop titled, “Trust Your Gut” – Therapeutic Opportunities from the Microbiome. The panel was moderated by Mark Breidenbach, PhD, Equity Research Group, H.C. Wainwright & Co. The panelists were: Martin J. Blaser, MD, Muriel and George Singer Professor of Medicine, Professor of Microbiology, Director, Human Microbiome Program, New York University Langone Medical Center Karim Dabbagh, PhD, Chief Scientific Officer, Second Genome Michael Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Session Recap: Digital Health—Early Successes for Investors and Biotech R&D Productivity

shutterstock_27160801

Digital health has the potential to improve the life science industry by combining traditional and novel medicines with digital technologies, enabling the life sciences to become more patient-centered as well as accelerating product discovery. There is growing interest in digital health among investors as new data and technologies become available that fill unmet needs in the marketplace. At the 17th Annual BIO CEO & Investor Conference, a panel of digital health experts came together to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Investor Forum Closing Plenary: How Fragile is the Biotech Rally After Five Positive Years?

2

Last week’s 13th Annual BIO Investor Forum closed on Wednesday with a plenary session asking, “How fragile is the biotech rally after five positive years?” Moderated by Todd Foley, Managing Director, MPM Capital, the panel included: Rachel King, CEO, GlycoMimetics and Chair, BIO Ellen Lubman, VP Strategy and Innovation, Forest Laboratories Vijay Murthy, Director, Ventures and Early Stage Collaborations, AbbVie Michael A. Margolis, RPh, Managing Director, ROTH Capital Partners Doug Fambrough, PhD, CEO, Dicerna Pharmaceuticals Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

2014 BIO Investor Forum Fireside Chat with Nick Leschly and Chris Collins

bluebird bio

Nick Leschly has served as bluebird bio’s president and chief executive officer since September 2010. Previously, he served as interim chief executive officer from March 2010 to September 2010. Formerly a partner of Third Rock Ventures, L.P. since its founding in 2007, Mr. Leschly played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Gene Therapies Discussed at 2014 BIO Investor Forum

BIO Investor Forum

Since the great excitements and disappointments of gene therapy’s first clinical era, the 1990s, researchers have revised traditional approaches and developed innovative new techniques, including CRISPR/cas-9, to edit genes with greater speed and precision than ever before.  Across a wide range of diseases, gene therapy is showing traction with fresh clinical results and attracting more than $600 million in venture capital in the past two years.  However, real challenges remain in delivery of therapies in Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,